Aptamers Market Trends with Industry Study & Forecast to 2023

Market Scope

Aptamers market 2020 is on track to achieve a significant growth rate of 20.2% over the review period (from 2018 to 2023), reveals MRFR (Market Research Future). We will provide COVID-19 impact analysis with the report, along with all the extensive key developments in the market post the coronavirus disease outbreak.

Key Impacting Factors and Barriers

Aptamers are gaining widespread interest of scientists, as a multifunctional molecule that offers a number of benefits compared to the well-known antibodies. For instance, aptamers help reduce the period of time generally required for benchmark testing, saving close to 35% of the overall cost and numerous years of research and development (R&D) of these molecules. Other advantages include significant thermal stability, lower chance of triggering unnecessary immune responses, and cost effectives, which help bolster its demand and use. The aptamers market has been gaining strength across countries, with the increase in government support, mounting awareness among manufacturers, and potential pipelines.

A number of research activities over the years have revealed that the medication method or functional mechanism of the aptamer is quite similar to the antibodies. These studies have helped the market get the attention of a large number of investors. The number of firms that are striving to explore the application scope of the molecule across diverse medical areas has increased splendidly in the last few years, which also favors the market growth. Another key development can be the fast surge in the number of small sized enterprises and startups trying to capture the unleveraged growth potential of the aptamers industry. Companies like Aptamer Sciences, Inc., Aptamer Group and Aptagen LLC are some of the top players that are expected to face tough competition from the new entrants in the following years, giving a major push to the market growth.

Many of the key market contenders are concentrating on intensive R&D activities to come up with novel and advanced aptamers to cater to a broader range of medical use-cases. Big names in the pharmaceutical industry such as Merck & Co., Inc., Eli Lilly & Company, and more are spending generously on oligonucleotide therapy. Some of vendors are also collaborating with smaller manufacturers to bolster their market presence. To illustrate, in October 2020, Qualigen Therapeutics Inc. entered an agreement with the University of Louisville to accelerate the advancement of its study that focuses on an anticancer drug candidate AS1411-GNP, also known as Aptamer-Linked Anti-Nucleolin (ALAN). The primary objective of the study is to analyze the antitumor efficiency along with the safety aspect of various ALAN compositions for the treatment of adult and pediatric acute myeloid leukemia.

Affluent Competitors

Some of the most affluent industry competitors are Aptamer Solutions Ltd., Trilink Biotechnologies Inc., Vivonics, Inc., Aptamer Sciences, Inc., Aptus Biotech S.L., Base Pair Biotechnologies, Inc., Somalogic, Inc., Am Biotechnologies, LLC, Ophthotech Corporation, Noxxon Pharma, Aptagen, LLC, Neoventures Biotechnology Inc., and more.

Article source: https://article-realm.com/article/Sports-Recreation/13017-Aptamers-Market-Trends-with-Industry-Study-and-Forecast-to-2023.html